Lynchburg Journal of Medical Science

Lynchburg Journal of Medical Science


Emergency Medicine


Dr. Nancy Reid


As of 2018, Truvada® has been considered the only treatment for PrEP®, and the only medication used to prevent the transmission of the Human Immunodeficiency Virus (HIV); until the United States Food and Drug Administration (FDA) approved Descovy® as a second medication in 2019. While the research dictates the efficacy of Descovy® to be up to par with Truvada®, Descovy® may actually be more beneficial to certain patients in certain scenarios. While the goal is to move forth with a medication that provides better outcomes and an overall decrease in side effects, further research is necessary to determine which of the two is by far superior.


Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.

Off-campus users can also use 'Off-campus Download' button above for access.